CN112773849A - Pharmaceutical composition for preventing pet anxiety and application thereof - Google Patents
Pharmaceutical composition for preventing pet anxiety and application thereof Download PDFInfo
- Publication number
- CN112773849A CN112773849A CN202011636350.9A CN202011636350A CN112773849A CN 112773849 A CN112773849 A CN 112773849A CN 202011636350 A CN202011636350 A CN 202011636350A CN 112773849 A CN112773849 A CN 112773849A
- Authority
- CN
- China
- Prior art keywords
- component
- pharmaceutical composition
- parts
- methyl
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a pharmaceutical composition for preventing pet anxiety and application thereof, wherein the active ingredients comprise, by mass, 0.1-1: 20-60 of component A and component B, wherein the component A is one or more of ligustilide, nepetalactone, jatamarine, valerian, actinidine, dihydroactinidine, limonene, phellandrene and asarone, and the component B is one or more of spina date seed oil, gardenia oil and valerian essential oil. The raw materials of the drug component A provided by the invention are natural drugs or volatile components in traditional Chinese medicines, can be mixed with the high boiling point component B in a mixing tank to form uniform mixed liquid which has good fluidity and is easy to spray, does not solidify at low temperature, has certain volatility and can be quickly released, and the high boiling point fatty oil component B can slowly release natural pheromone, so that anxiety and stress of the cat can be quickly and effectively prevented, and the behaviors of the cat such as urine collection, scratching, depression or attacking people can be eliminated.
Description
Technical Field
The invention relates to the technical field of veterinary drugs, and particularly relates to a pharmaceutical composition for preventing anxiety disorder of pets and application thereof.
Background
With the improvement of living standard of people, the aging of social population and the pressure of modern people are continuously increased, so that the number of domestic pets is increased, the medical care of the pets is increasingly concerned by the society, and the medical care of the pets in China is rapidly developed in nearly 10 years. The number of pet dogs in china is only this in the united states and brazil, and is third in the world. By 2018, the market scale of the Chinese pet dogs and cats reaches 1750 billion yuan. The economic market scale of pets is expected to break through 2000 billion yuan in 2020.
Although the pets accompany human beings, the pets can also have a certain degree of depression due to factors such as living environment and the like; in particular, although cats belong to very independent animals, there still exist cases of suffering from depression, for example, new guests at home, strange animals, things that suddenly appear, objects that suddenly move or change in the visual field, various noises, or going to a strange place, transportation, traveling out, punishment, cold fall, etc. all cause anxiety of cats, further cause stress behaviors or depression such as mental stress, urine collection at home marks, scratching of fabrics and furniture, attacking people, etc., and have serious suicide consequences such as mental depression, building jump, car crash, food death, etc. after the cat depression.
The anxiolytic drugs such as benzodiazepines, carbamates, diphenylmethane and the like are listed abroad, the anxiolytic drugs such as tylosin, meprobamate, carisoprodol and the like are listed on the market, but the drugs have great side effects on dogs and cats, are rarely used on dogs and cats, and need to be taken orally for a long time, and can not effectively prevent anxiety generation in time.
By inquiring the existing market products, the related reports of the pharmaceutical composition for preventing the anxiety disorder of the pets, which has quick response and long action, are not seen yet.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for preventing pet anxiety, which has definite curative effect, quick response and long action.
The invention also aims to provide application of the pharmaceutical composition for preventing anxiety disorder of pets.
The invention adopts the following technical scheme:
a pharmaceutical composition for preventing anxiety of pets comprises the following active components in a mass ratio of 0.1-1: 20-60 of component A and component B.
The component A is one or more of ligustilide, nepetalactone, jatamarin, valerian, actinidine, dihydroactinidine, limonene, phellandrene and asarone.
The component B is one or more of wild jujube kernel oil, gardenia oil and valerian essential oil.
Preferably, in the above technical solution, the mass ratio of the component a to the component B is 0.2-0.7: 30-60.
Further, in the above technical scheme, the pharmaceutical composition for preventing anxiety disorder of pets further comprises one or more of a solvent, a preservative, an antioxidant and a pH regulator.
Preferably, in the above technical solution, the pH adjusting agent is added in an amount to control the pH of the pharmaceutical composition to 7.0-7.8.
In a specific embodiment of the present invention, the solvent is one or more of diethylene glycol monoethyl ether, glycerol, ethyl oleate, methyl linoleate, isopropyl myristate, glyceryl stearate, glyceryl oleate and lanolin.
In a particular embodiment of the invention, the preservative is methylparaben.
In a particular embodiment of the invention, the antioxidant is 2, 6-di-tert-butyl methylphenol.
In a specific embodiment of the present invention, the pH adjusting agent is one or more of triethanolamine, sodium lactate, lactic acid, palmitic acid, butyric acid, and propionic acid.
In a specific embodiment of the invention, the pharmaceutical composition for preventing anxiety disorder of pets comprises the following raw materials in parts by weight:
0.2-0.7 part of component A, 30-60 parts of component B, 40-70 parts of solvent, 0.001-0.01 part of preservative, 0.005-0.2 part of antioxidant and 0.001-0.1 part of pH regulator.
In a preferred embodiment of the invention, the pharmaceutical composition for preventing anxiety disorder of pets comprises the following raw materials in parts by weight:
0.4 to 0.58 portion of nepetalactone, 30 to 42.8 portions of wild jujube kernel oil, 65 to 70 portions of diethylene glycol monoethyl ether, 0.001 to 0.01 portion of methyl p-hydroxybenzoate, 0.005 to 0.02 portion of 2, 6-di-tert-butyl methyl benzene and 0.001 to 0.01 portion of triethanolamine/lactic acid.
In a preferred embodiment of the invention, the pharmaceutical composition for preventing anxiety disorder of pets comprises the following raw materials in parts by weight:
0.25-0.48 part of actinidine, 48-60 parts of gardenia oil, 35-50 parts of methyl linoleate, 0.001-0.01 part of methyl p-hydroxybenzoate, 0.005-0.02 part of 2, 6-di-tert-butyl methylbenzene and 0.001-0.01 part of triethanolamine/lactic acid.
In a preferred embodiment of the invention, the pharmaceutical composition for preventing anxiety disorder of pets comprises the following raw materials in parts by weight:
0.45 to 0.62 portion of valerian, 34.5 to 42.8 portions of wild jujube kernel oil, 8.5 to 11.8 portions of methyl oleate, 16.8 to 21.5 portions of glyceryl stearate, 36.5 to 45.2 portions of lanolin, 0.005 to 0.01 portion of methyl p-hydroxybenzoate, 0.01 to 0.02 portion of 2, 6-di-tert-butyl methylbenzene and 0.001 to 0.01 portion of triethanolamine/lactic acid.
In a preferred embodiment of the invention, the pharmaceutical composition for preventing anxiety disorder of pets comprises the following raw materials in parts by weight:
0.25-0.36 part of valeriana jatamansi essence, 31.8-38.6 parts of gardenia oil, 8.5-12.6 parts of methyl oleate, 802.4-3.5 parts of tween, 48.8-56.8 parts of polyethylene glycol, 0.005-0.01 part of methyl p-hydroxybenzoate, 0.01-0.02 part of 2, 6-di-tert-butyl methylbenzene and 0.001-0.005 part of triethanolamine/lactic acid.
The invention also provides application of the pharmaceutical composition in preparing a medicine for preventing anxiety disorder of pets.
Compared with the prior art, the invention has the beneficial effects that:
the raw materials of the pharmaceutical composition for preventing the anxiety disorder of the pet provided by the invention are natural medicines or volatile components in traditional Chinese medicines, have the effects of tranquilizing and allaying excitement and being pleasant to mind, can be mixed into uniform mixed liquid which has good fluidity and is easy to spray in a mixing tank, does not solidify at low temperature, has certain volatility, can be quickly released, contains high-boiling-point fatty oil, can slowly release natural pheromone, allows the cat to quickly and durably smell the smell of the liquid medicine, allows the pet to be in a pleasant, relaxed and quiet state when the pet is alone dull or faces strange and special environments, allows the cold and quiet state to face uncomfortable environments, effectively prevents anxiety and stress of the cat, further eliminates the behaviors of the cat such as urine, scratching, depression or aggressors, allows the pet to be in a quiet state, reduces autonomous behaviors and has a pleasant mood, the anxiety of the pet is relieved, and the physical and psychological health of the pet is well protected.
Detailed Description
The present invention is further described in detail below with reference to specific examples so that those skilled in the art can more clearly understand the present invention.
The following examples are given for the purpose of illustration only and are not intended to limit the scope of the invention.
All other embodiments obtained by a person skilled in the art based on the specific embodiments of the present invention without any inventive step are within the scope of the present invention.
In the examples of the present invention, all the raw material components are commercially available products well known to those skilled in the art unless otherwise specified.
In the examples of the present invention, unless otherwise specified, all technical means used are conventional means well known to those skilled in the art.
Example 1
1. Composition of raw materials
2. Preparation method
Putting nepetalactone, spina date seed oil, diethylene glycol monoethyl ether, methyl p-hydroxybenzoate and 2, 6-di-tert-butyl methyl phenol into a mixing tank, mixing uniformly, adjusting pH value to 7.4 with triethanolamine and lactic acid, and bottling into a spray bottle to prepare into spray.
Example 2
2. Preparation method
Placing actinidine, gardenia oil and methyl linoleate into a mixing tank, mixing uniformly, placing methyl p-hydroxybenzoate and 2, 6-di-tert-butyl methyl phenol into the mixing tank, mixing uniformly, adjusting pH to 7.4 with triethanolamine and lactic acid, and bottling into drop bottle to obtain drop.
Example 3
2. Preparation method
Putting valerianin, spina date seed oil, methyl oleate, glyceryl stearate and lanolin in a mixing tank, heating for melting, mixing, putting methyl hydroxybenzoate and 2, 6-di-tert-butyl methyl phenol in the mixing tank, mixing, adjusting pH to 7.4 with triethanolamine and lactic acid, bottling in an ointment hose, sealing, and making into ointment.
Example 4
1. Composition of raw materials
2. Preparation method
Adding the valeriana jatamansi essence, the gardenia oil, the methyl oleate, the Tween 80 and the polyethylene glycol into a mixing tank, heating and melting, uniformly mixing, adding the methyl p-hydroxybenzoate and the 2, 6-di-tert-butyl methyl phenol into the mixing tank, uniformly mixing, adjusting the pH value to 7.4 by using triethanolamine and lactic acid, filling into a gel hose, sealing, and preparing into a gel.
Comparative example 1
1. Composition of raw materials
2. Preparation method
Mixing semen Ziziphi Spinosae oil, diethylene glycol monoethyl ether, methyl p-hydroxybenzoate and 2, 6-di-tert-butyl methyl phenol in a mixing tank, adjusting pH to 7.4 with triethanolamine and lactic acid, and bottling in spray bottle to obtain spray
Comparative example 2
1. Composition of raw materials
2. Preparation method
Putting valerianin, spina date seed oil, methyl oleate, glyceryl stearate and lanolin in a mixing tank, heating for melting, mixing, putting methyl hydroxybenzoate and 2, 6-di-tert-butyl methyl phenol in the mixing tank, mixing, adjusting pH to 7.4 with triethanolamine and lactic acid, bottling in an ointment hose, sealing, and making into ointment.
And (3) comparing test effects:
1. data relating to comparative tests
210 pet cats of similar weight and age were randomly divided into 7 groups, including experimental groups 1-4, control groups 1-2, and placebo groups, with 30 cats in each group.
The test method comprises the following steps:
experimental groups 1 to 4 were treated with clinical trials using the pharmaceutical composition preparations of examples 1 to 4, respectively;
the control groups 1-2 were treated clinically with the pharmaceutical composition preparations of comparative examples 1-2, respectively;
the placebo group performed a comparative experiment using distilled water.
The test time includes 10min, 30min, 60min, 12h and 24 h.
The observation indexes of clinical curative effect are as follows:
anxiety states of the cats were observed, including stress, licking hair, shooting urine, scratching clothes, etc.
Comprehensive index: clinical index of cat anxiety and index of cat discomfort, obtained by increasing the score of the respective component in each examination item.
And (3) evaluating the clinical curative effect: and evaluating by using a clinical symptom integral reduction index.
The evaluation criteria are as follows:
level 0: no obvious clinical symptoms appear, the performance is good, and the phenomena of nervous spirit, licking hair, shooting urine, grabbing and biting clothes and the like do not exist;
level 1: the anxiety degree is light, the spirit is nervous, the occurrence frequency of licking hair, jetting urine, scratching clothes and the like is low;
and 2, stage: the anxiety degree is moderate, the spirit is nervous, the occurrence frequency of licking hair, jetting urine, grabbing and biting clothes and the like is high;
and 3, level: anxiety is serious, and the occurrence frequency of nervous spirit, licking hair, shooting urine, scratching clothes and the like is frequent.
The clinical symptom score reduction index is (total score before drug administration-total score after drug administration)/total score before drug administration × 100%.
And (3) comprehensive curative effect evaluation:
evaluation criteria were counted as cure, effect and ineffectiveness, and analyzed in comparison with the biological statistics of the placebo group.
And (3) curing: after the medicine is taken, the anxiety symptom is obviously disappeared, the spirit is tense, the hair licking, the urine shooting, the clothes grabbing and biting and the like are obviously disappeared, and the integral reduction index of the clinical symptom is more than or equal to 90 percent.
The effect is shown: after the medicine is taken, the anxiety symptom is obviously disappeared, the spirit is tense, the clothes are obviously disappeared by licking hair, shooting urine, grabbing and biting clothes and the like, and the integral reduction index of the clinical symptom is 60-90%.
The method has the following advantages: after the medicine is taken, anxiety symptoms are relieved, nervous spirit, licking hair, shooting urine, grabbing and biting clothes and the like are reduced, and the integral reduction index of clinical symptoms is 20-60%.
And (4) invalidation: after the medicine is taken, the mental stress, the hair licking, the urine jetting, the clothes grabbing and biting and the like are not reduced, the inflammatory secretion still exists, and the integral reduction index of the clinical symptoms is less than or equal to 20 percent.
The results of the prevention anxiety and the clinical treatment rating after introduction to strange cats are shown in tables 1 and 2, respectively.
TABLE 1 preventive anxiety outcomes in cats following introduction of strange cats
Table 2 clinical treatment rating results at various times after introduction of strange cats
As can be seen from tables 1-2, the clinical symptom score indices for the cats in experimental groups 1-4 were significantly lower after introduction of strange cats.
Specifically, in the first 1 hour in the test process, after the medicine is taken (test groups 1-4), anxiety symptoms obviously disappear, and the patient feels nervous, licks hair, shoots urine and grabs clothes (the integral of clinical symptoms is reduced by 60-90%); the anxiety symptom disappears obviously in 24 hours, and the feeling is tense, the clothes are licked, jetted and bitten (the integral reduction index of the clinical symptom is more than or equal to 90 percent); compared with the control group 1-2, the experimental group 1-4 has obvious effect of 60-90% of the integral reduction index of clinical symptoms in 1min, 10min and 30min, while the control group 1-2 is only effective, and the integral reduction index of clinical symptoms is 20-60%, thus the experimental group 1-4 can quickly exert curative effect after being taken relative to the control group 1-2; after 48 hours, the experimental group 1-4 and the control group 1-2 can achieve obvious curative effect, both have long-acting effect, and the long-term curative effect of the experimental group 1-4 is obviously better than that of the control group 1-2.
The results of anxiety prevention and clinical treatment ratings during long-distance transport are shown in tables 3 and 4 below, respectively.
TABLE 3 preventive anxiety outcomes in cats in long haul transport
TABLE 4 clinical treatment rating results at different times during long-distance transport
As can be seen from tables 3-4, the clinical symptom score indices for the cats in test groups 1-4 were significantly lower during transport.
Specifically, in the first 1 hour in the test process, after the medicine is taken (test groups 1-4), anxiety symptoms obviously disappear, and the patient feels nervous, licks hair, shoots urine and grabs clothes (the integral of clinical symptoms is reduced by 60-90%); the anxiety symptom disappears obviously in 24 hours, and the feeling is tense, the clothes are licked, jetted and bitten (the integral reduction index of the clinical symptom is more than or equal to 90 percent); compared with the control group 1-2, the experimental group 1-4 has obvious effect of 60-90% of the integral reduction index of clinical symptoms in 1min, 10min and 30min, while the control group 1-2 is only effective, and the integral reduction index of clinical symptoms is 20-60%, thus the experimental group 1-4 can quickly exert curative effect after being taken relative to the control group 1-2; after 48 hours, the experimental group 1-4 and the control group 1-2 can achieve obvious curative effect, both have long-acting effect, and the long-term curative effect of the experimental group 1-4 is obviously better than that of the control group 1-2.
Finally, the method of the present invention is only a preferred embodiment and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A pharmaceutical composition for preventing anxiety of pets,
the active ingredients of the composition comprise, by mass, 0.1-1: 20-60 of component A and component B;
the component A is one or more of ligustilide, nepetalactone, jatamarin, valerian, actinidine, dihydroactinidine, limonene, phellandrene and asarone;
the component B is one or more of wild jujube kernel oil, gardenia oil and valerian essential oil.
2. The pharmaceutical composition for preventing anxiety in pets according to claim 1,
the mass ratio of the component A to the component B is 0.2-0.7: 30-60.
3. The pharmaceutical composition for preventing anxiety in pets according to claim 1,
also comprises one or more of a solvent, a preservative, an antioxidant and a pH regulator;
preferably, the pH regulator is added in an amount to control the pH of the pharmaceutical composition to 7.0-7.8.
4. The pharmaceutical composition for preventing anxiety in pets according to claim 3,
the solvent is one or more of diethylene glycol monoethyl ether, glycerol, ethyl oleate, methyl linoleate, isopropyl myristate, glyceryl stearate, vomit, polyethylene glycol, glyceryl oleate and lanolin;
and/or the preservative is methyl p-hydroxybenzoate;
and/or the antioxidant is 2, 6-di-tert-butyl methyl phenol;
and/or the pH regulator is one or more of triethanolamine, sodium lactate, lactic acid, palmitic acid, oleic acid, linoleic acid, butyric acid and propionic acid.
5. The pharmaceutical composition for preventing anxiety in pets according to any of claims 1 to 4,
the composition is characterized by comprising the following raw materials in parts by weight: 0.2-0.7 part of component A, 30-60 parts of component B, 40-70 parts of solvent, 0.001-0.01 part of preservative, 0.005-0.2 part of antioxidant and 0.001-0.1 part of pH regulator.
6. The pharmaceutical composition for preventing anxiety in pets according to claim 5,
the composition is characterized by comprising the following raw materials in parts by weight: 0.2 to 0.58 portion of nepetalactone, 30 to 42.8 portions of wild jujube kernel oil, 65 to 70 portions of diethylene glycol monoethyl ether, 0.001 to 0.01 portion of methyl p-hydroxybenzoate, 0.005 to 0.02 portion of 2, 6-di-tert-butyl methyl benzene and 0.001 to 0.01 portion of triethanolamine/lactic acid.
7. The pharmaceutical composition for preventing anxiety in pets according to claim 5,
the composition is characterized by comprising the following raw materials in parts by weight: 0.25-0.48 part of actinidine, 48-60 parts of gardenia oil, 35-50 parts of methyl linoleate, 0.001-0.01 part of methyl p-hydroxybenzoate, 0.005-0.02 part of 2, 6-di-tert-butyl methylbenzene and 0.001-0.01 part of triethanolamine/lactic acid.
8. The pharmaceutical composition for preventing anxiety in pets according to claim 5,
the composition is characterized by comprising the following raw materials in parts by weight: 0.45 to 0.62 portion of valerian, 34.5 to 42.8 portions of wild jujube kernel oil, 8.5 to 11.8 portions of methyl oleate, 16.8 to 21.5 portions of glyceryl stearate, 36.5 to 45.2 portions of lanolin, 0.001 to 0.01 portion of methyl p-hydroxybenzoate, 0.005 to 0.02 portion of 2, 6-di-tert-butyl methylbenzene and 0.001 to 0.01 portion of triethanolamine/lactic acid.
9. The pharmaceutical composition for preventing anxiety in pets according to claim 5,
the composition is characterized by comprising the following raw materials in parts by weight: 0.25-0.36 part of valeriana jatamansi essence, 31.8-38.6 parts of gardenia oil, 8.5-12.6 parts of methyl oleate, 802.4-3.5 parts of tween, 48.8-56.8 parts of polyethylene glycol, 0.001-0.01 part of methyl p-hydroxybenzoate, 0.005-0.02 part of 2, 6-di-tert-butyl methylbenzene and 0.001-0.01 part of triethanolamine/lactic acid.
10. Use of a pharmaceutical composition according to any one of claims 1 to 9 for the manufacture of a medicament for the prevention of anxiety in pets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011636350.9A CN112773849A (en) | 2020-12-31 | 2020-12-31 | Pharmaceutical composition for preventing pet anxiety and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011636350.9A CN112773849A (en) | 2020-12-31 | 2020-12-31 | Pharmaceutical composition for preventing pet anxiety and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112773849A true CN112773849A (en) | 2021-05-11 |
Family
ID=75754918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011636350.9A Pending CN112773849A (en) | 2020-12-31 | 2020-12-31 | Pharmaceutical composition for preventing pet anxiety and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112773849A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716275A (en) * | 2011-03-31 | 2012-10-10 | 石晋丽 | Detection method of anti-anxiety pharmaceutical composition |
| CN104886568A (en) * | 2015-05-13 | 2015-09-09 | 中国中轻国际工程有限公司 | Wild jujube seed oil soft capsule production technology |
-
2020
- 2020-12-31 CN CN202011636350.9A patent/CN112773849A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716275A (en) * | 2011-03-31 | 2012-10-10 | 石晋丽 | Detection method of anti-anxiety pharmaceutical composition |
| CN104886568A (en) * | 2015-05-13 | 2015-09-09 | 中国中轻国际工程有限公司 | Wild jujube seed oil soft capsule production technology |
Non-Patent Citations (4)
| Title |
|---|
| 彭敏，等: "蜘蛛香抗焦虑复方的抗焦虑作用及其机制", 《中草药》 * |
| 李宝莉，等: ""不同提取工艺的酸枣仁油对小鼠镇静催眠作用的影响"，", 《西安交通大学学报(医学版)》 * |
| 李宝莉，等: "栀子油的提取和对中枢神经系统的作用", 《第四军医大学学报》 * |
| 翟欣，等: "蜘蛛香提取物及总缬草素的抗焦虑活性研究", 《中草药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5472713A (en) | Therapeutic uses of emu oil | |
| DE69922633T2 (en) | Pheromone-containing composition for reducing stress, anxiety and contentiousness in pigs | |
| CN111388372A (en) | Plant composition for dispelling mosquitoes, cooling and relieving itching and preparation method thereof | |
| CN110638727A (en) | Infant hip-protecting composition and preparation method and application thereof | |
| CN106511580A (en) | Itching relieving composition and application thereof | |
| CN113995693B (en) | Essence composition of liposome with anti-inflammatory effect, and preparation method and application thereof | |
| CN112773849A (en) | Pharmaceutical composition for preventing pet anxiety and application thereof | |
| CN111329806A (en) | Allergy-relieving repair anti-inflammatory composition and preparation method thereof | |
| CN110248702A (en) | The composition useful for the cosmetic treatments of Oily | |
| CN113143804B (en) | Plant composition and application thereof | |
| CN113893297A (en) | New application of pharmaceutical composition in preparation of medicines for treating thyrotoxicosis | |
| CN113577185A (en) | Essential oil self-microemulsion for improving laying fowl salpingitis and preparation method thereof | |
| CN114681353A (en) | Skin itching-relieving and soothing liquid suitable for infants and preparation method thereof | |
| CN115770267B (en) | Infantile eczema ointment and preparation method thereof | |
| CN111249168A (en) | Composition for preventing mosquito bites and preparation method thereof | |
| Sudira et al. | Influence of dietary natural veterinary medicine (Minyak rajas) on growth performance and blood profile of growing roosters | |
| CN106943505B (en) | Traditional Chinese medicine composition for resisting prenatal stress syndrome for dogs and preparation method thereof | |
| Shi et al. | Effects of traditional chinese medicine on numbers of lymphocytes and goblet cells in villus epithelia of layers under heat stress | |
| CN112972437B (en) | Long-acting external preparation containing iodonitrophenol and preparation method and application thereof | |
| CN116098839B (en) | Oil-soluble composition with relieving itching function and preparation method thereof | |
| CN115778834B (en) | Mosquito-repellent composition and application thereof | |
| CN116035944B (en) | Bionic fetal fat composition, cosmetic and preparation method thereof | |
| CN113577023B (en) | Triazamidine suspension injection and preparation method thereof | |
| CN112107525A (en) | External composition for relieving skin eczema, infant skin care product and preparation method of external composition | |
| KR20240037292A (en) | Dermatological collars for non-human animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210511 |